The raphe serotonergic system plays a pivotal role in migraine pathophysiology, serving as a critical interface between brainstem pain modulatory circuits and the trigeminovascular system responsible for migraine pain. Raphe nuclei, particularly the dorsal raphe nucleus (DRN) and median raphe nucleus (MRN), contain the majority of forebrain-projecting serotonergic neurons and are strategically positioned to modulate pain perception, arousal, mood, and autonomic function—all of which are perturbed during migraine attacks [1].
Serotonin (5-hydroxytryptamine, 5-HT) has been central to migraine theory since the 1950s, when elevated platelet serotonin levels were first observed during migraine attacks. This discovery led to the serotonin hypothesis of migraine and ultimately to the development of triptans, the first migraine-specific acute treatments [2].
The raphe nuclei consist of nine anatomically distinct nuclei (B1-B9) distributed along the midline of the brainstem, from the medulla to the midbrain. For migraine research, the most relevant are:
Dorsal Raphe Nucleus (DRN, B6/B7): The largest serotonergic nucleus, containing about 35% of all brain serotonergic neurons. The DRN projects extensively to the forebrain, including the hypothalamus, thalamus, basal ganglia, hippocampus, and cerebral cortex. It receives input from the trigeminal nucleus caudalis and periaqueductal gray, creating a pain-modulatory circuit [3].
Median Raphe Nucleus (MRN, B8): Projects primarily to the hippocampus and septum. The MRN is less involved in pain modulation but plays important roles in arousal and mood regulation, which are comorbid with chronic migraine [4].
Raphe Magnus (RMg, B3): Located in the medulla, projects to the spinal cord dorsal horn. This nucleus is critical for descending pain inhibition via 5-HT1A and 5-HT1B receptors on spinal cord neurons [5].
Raphe serotonergic neurons synthesize 5-HT from the essential amino acid tryptophan via a two-step enzymatic process: tryptophan hydroxylase (TPH2, the rate-limiting enzyme) converts tryptophan to 5-hydroxytryptophan, which is then decarboxylated by aromatic L-amino acid decarboxylase (AADC) to form 5-HT [6].
Key receptor subtypes implicated in migraine:
| Receptor | Location | Migraine Relevance |
|---|---|---|
| 5-HT1A | Autoreceptor (soma), postsynaptic | Pain modulation, mood |
| 5-HT1B | Vascular smooth muscle | Vasoconstriction (triptan target) |
| 5-HT1D | Trigeminal nerve terminals | Inhibition of CGRP release |
| 5-HT1F | Trigeminal ganglion | Triptan target, no vasoconstriction |
| 5-HT2A | Cortex, platelets | Vasodilation, platelet activation |
| 5-HT2C | Choroid plexus | CSF production, migraine aura |
Serotonergic neurons exhibit distinctive firing patterns:
The firing rate of DRN neurons is positively correlated with cortical arousal and negatively correlated with migraine attack frequency in chronic migraine patients [7].
The original serotonin hypothesis proposed that migraine attacks are triggered by a sudden decrease in plasma serotonin, leading to cranial vasodilation and subsequent rebound increase in 5-HT metabolite 5-HIAA in urine [2:1]. Modern understanding has refined this to:
The trigeminovascular system is the final common pathway for migraine pain. C-fiber and Aδ-fiber afferents from the meninges converge on second-order neurons in the trigeminal nucleus caudalis (TNC), which project to the thalamus and then cortex [9].
Raphe serotonergic neurons modulate this system at multiple levels:
Cortical spreading depression (CSD) is the neural correlate of migraine aura. Recent evidence suggests serotonergic mechanisms participate in CSD initiation and propagation:
Functional imaging studies have identified the brainstem as critical for migraine attack generation. The DRN shows increased activity during migraine attacks, even in the absence of pain (premonitory phase), suggesting it functions as an aura generator or pain trigger [13].
The primary excitatory neurotransmitter in the trigeminovascular system interacts with serotonergic modulation:
Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine:
GABAergic neurons in the DRN provide inhibitory feedback:
Dopaminergic pathways interact with serotonergic systems in migraine:
Concurrent use of serotonergic medications (triptans plus SSRIs/SNRIs) carries theoretical risk of serotonin syndrome, characterized by:
However, large database studies have not confirmed increased risk with triptan-antidepressant combinations [19].
Chronic triptan use (more than 10 days per month) can lead to medication-overuse headache:
The raphe serotonergic system represents a critical node in migraine pathophysiology, integrating signals from cortical, brainstem, and spinal pain pathways. Serotonergic agents have been foundational to migraine therapy for decades, and ongoing research continues to refine our understanding of 5-HT receptor subtypes and their roles in migraine generation and modulation.
Future directions include:
Goadsby PJ, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2022. 2022. ↩︎
Sicuteri F. Headache: the changing meaning of serotonin. Funct Neurol. 1990. 1990. ↩︎ ↩︎
Michelsen KA, et al. The dorsal raphe nucleus: from gold chloride to neuropeptide imaging. Headache. 2017. 2017. ↩︎
Abrams JK, et al. Neurochemistry and pharmacology of the median raphe nucleus. J Neural Transm. 2004. 2004. ↩︎
Fields HL, et al. Serotonergic pain modulation from the rostral ventromedial medulla. Pain. 2007. 2007. ↩︎
Walther DJ, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003. 2003. ↩︎
Cespuglio R, et al. Serotonergic raphe neurons in migraine. Cephalalgia. 2009. 2009. ↩︎
Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013. 2013. ↩︎
Humphrey PP, et al. 5-Hydroxytryptamine and migraine. Cephalalgia. 2008. 2008. ↩︎
Ducrot A, et al. Lasmiditan: the first selective 5-HT1F agonist. Cephalalgia. 2020. 2020. ↩︎ ↩︎
Ait-Daoud N, et al. Serotonin 5-HT2A receptors in cortical spreading depression. Cephalalgia. 2018. 2018. ↩︎
Denuelle M, et al. Brainstem activation in spontaneous migraine attacks. Cephalalgia. 2007. 2007. ↩︎
Edvinsson L, et al. CGRP and serotonin in migraine. Nat Rev Neurol. 2018. 2018. ↩︎
Schroeder BA, et al. GABAergic modulation of trigeminal pain. Cephalalgia. 2015. 2015. ↩︎
Charbit AR, et al. Dopamine and migraine. Cephalalgia. 2010. 2010. ↩︎
Sternfeld M, et al. Serotonergic antidepressants in migraine prevention. Headache. 2005. 2005. ↩︎
Martelletti P, et al. Serotonin transporter modulators in migraine. J Headache Pain. 2019. 2019. ↩︎
Wenzel RG, et al. Triptans and serotonin syndrome. Headache. 2002. 2002. ↩︎